Proposed Data Collections Submitted for Public Comment and Recommendations, 36550-36551 [2013-14435]

Download as PDF 36550 Federal Register / Vol. 78, No. 117 / Tuesday, June 18, 2013 / Notices Parts Closed to the Public DEPARTMENT OF HEALTH AND HUMAN SERVICES 1. Procurement 2. Security CONTACT PERSON FOR MORE INFORMATION: Kimberly Weaver, Director, Office of External Affairs, (202) 942–1640. [60Day–13–13XA] Proposed Data Collections Submitted for Public Comment and Recommendations Dated: June 13, 2013. James B. Petri, Secretary, Federal Retirement Thrift Investment Board. [FR Doc. 2013–14524 Filed 6–14–13; 11:15 am] BILLING CODE 6760–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Determination Concerning a Petition To Add a Class of Employees to the Special Exposure Cohort National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention, Department of Health and Human Services (HHS). AGENCY: ACTION: Notice. HHS gives notice of a determination concerning a petition to add a class of employees from the Brookhaven National Laboratory in Upton, New York, to the Special Exposure Cohort (SEC) under the Energy Employees Occupational Illness Compensation Program Act of 2000 (EEOICPA). On June 7, 2013, the Secretary of HHS determined that the following class of employees does not meet the statutory criteria for addition to the SEC as authorized under EEOICPA: SUMMARY: All employees of the Department of Energy, its predecessor agencies, and its contractors and subcontractors who worked at Brookhaven National Laboratory in Upton, New York, from January 1, 1994, to December 31, 2007. mstockstill on DSK4VPTVN1PROD with NOTICES FOR FURTHER INFORMATION CONTACT: Stuart L. Hinnefeld, Director, Division of Compensation Analysis and Support, National Institute for Occupational Safety and Health (NIOSH), 4676 Columbia Parkway, MS C–46, Cincinnati, OH 45226, Telephone 1– 877–222–7570. Information requests can also be submitted by email to DCAS@CDC.GOV. Dated: June 11, 2013. John Howard, Director, National Institute for Occupational Safety and Health. [FR Doc. 2013–14389 Filed 6–17–13; 8:45 am] BILLING CODE 4163–19–P VerDate Mar<15>2010 16:52 Jun 17, 2013 Jkt 229001 Centers for Disease Control and Prevention In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call 404–639–7570 or send comments to Ron Otten, 1600 Clifton Road, MS–D74, Atlanta, GA 30333 or send an email to omb@cdc.gov. Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Written comments should be received within 60 days of this notice. Proposed Project Improving HIV Prevention and Treatment Outcomes Among HIVInfected Persons by Integrating Community Pharmacists and Clinical Sites into a Model of Patient-Centered HIV Care—New—National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC). Background and Brief Description Medication Therapy Management (MTM) is a group of pharmacist provided services that is independent of, but can occur in conjunction with, provision of medication. Medication Therapy Management encompasses a broad range of professional activities and cognitive services within the licensed pharmacists’ scope of practice and can include monitoring prescription filling patterns and timing of refills, checking for medication interactions, PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 patient education, and monitoring of patient response to drug therapy. HIV specific MTM programs have demonstrated success in improving HIV medication therapy adherence and persistence. While MTM programs have be shown to be effective in increasing medication adherence for HIV-infected persons, no MTM programs have been expanded to incorporate primary medical providers in an effort to establish patient-centered HIV care. To address this problem CDC has entered into a public-private partnership with Walgreen Company (a.k.a Walgreens pharmacies, a national retail pharmacy chain) to develop and implement a model of HIV care that integrates community pharmacists with primary medical providers for patient-centered HIV care. The model program will be implemented in ten sites and will provide patient-centered HIV care for approximately 1,000 persons. The patient-centered HIV care model will include the core elements of MTM as well as additional services such as individualized medication adherence counseling, active monitoring of prescription refills and active collaboration between pharmacists and medical clinic providers to identify and resolve medication related treatment problems such as treatment effectiveness, adverse events and poor adherence. The expected outcomes of the model program are increased retention in HIV care, adherence to HIV medication therapy and viral load suppression. CDC requests OMB approval to collect standardized information, from ten project sites over the three year project period. CDC also requests approval to conduct one cycle of retrospective data collection during the first year of the three year project period. The retrospective data collection will provide information about clients’ baseline characteristics prior to participation in the model program which is needed to compare outcomes before and after program implementation. Pharmacy, laboratory and medical data will be collected through abstraction of all participant clients’ pharmacy and medical records. Pharmacy, laboratory and medical data are needed to monitor retention in care, adherence to therapy, viral load suppression and other health outcomes. Program specific data, such as the number of MTM elements completed per project site will be collected by program. Qualitative data will be gathered from program staff through inperson or telephone interviews. E:\FR\FM\18JNN1.SGM 18JNN1 36551 Federal Register / Vol. 78, No. 117 / Tuesday, June 18, 2013 / Notices The data collection will allow CDC to conduct continuous program performance monitoring which includes identification of barriers to program implementation, solutions to those barriers, and documentation of client health outcomes. Performance monitoring will allow the model program to be adjusted, as needed, in order to develop a final implementation model that is self-sustaining and which can be used to establish similar collaborations in a variety of clinical settings. There is no cost to participants other than their time. ESTIMATED ANNUALIZED BURDEN HOURS Number of responses per respondent Number of respondents Average burden per response (in hours) Total burden (in hours) Type of respondent Form name Clinic Data Manager ......................... Pharmacist ........................................ 10 10 1 1 30/60 30/60 5 5 Clinic Data Manager ......................... Clinic Data Manager ......................... Pharmacist ........................................ Clinic and pharmacy staff ................. Project clinic characteristics form ..... Project pharmacy characteristics form. Initial medical abstraction form ........ Follow-up medical abstraction form Pharmacy abstraction form .............. Interview form ................................... 10 10 10 60 1 4 4 4 50 25 25 45/60 500 1,000 1,000 180 Total ........................................... ........................................................... ........................ ........................ ........................ 2,690 Ron A. Otten, Director, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention. [FR Doc. 2013–14435 Filed 6–17–13; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Administration for Children and Families Submission for OMB Review; Comment Request Title: Form CB–496. ‘‘Title IV–E Programs Quarterly Financial Report’’. OMB No.: 0970–0205. Description: This report is required to be submitted at the end of each fiscal quarter by each State or Tribe with an approved plan under title IV–E of the Social Security Act to administer the Foster Care, Adoption Assistance and Guardianship Assistance programs. In submitting this form, each State or Tribal grantee meets its statutory and regulatory requirement to report actual program expenditures made in the preceding fiscal quarter and to provide an estimate of program expenditures anticipated in the upcoming fiscal quarter. This reporting form also provides for the quarterly reporting of the average number of children assisted through each of the three programs. The Administration for Children and Families provides Federal funding at the rate of 50 percent for all allowable administrative expenditures, with funding at higher rates for some training costs and maintenance assistance payments. The information collected on this report is used to calculate quarterly Federal grant awards issued to States and Tribes and to assist in the oversight of the financial management of these programs. With the enactment of Public Law 110–351, the ‘‘Fostering Connections to Success and Increasing Adoptions Act of 2008’’ (October 7, 2008), the Guardianship Assistance program started operation in FY 2009 and Tribes, tribal organizations and consortia became eligible to submit individual title IV–E plans in FY 2010. At the time of this request for OMB review, 33 States have had their State plan amendments submitted and approved to include the Guardianship program; additional States are anticipated in the future. To date, although only a single Tribal title IV–E plan has been approved, several additional Tribal plans are in the final stages of the review process, with approval anticipated shortly. Under Public Law 112–34, the ‘‘Child and Family Services Improvement and Innovation Act’’ (September 30, 2011), Section 1130 of the Social Security Act was amended to allow ACF to approve up to ten child welfare waiver demonstration projects in each of FYs 2012–2014. These projects are to continue no longer than five years and be completed no later than September 30, 2019, the end of FY 2019. The anticipated inclusion of thirty additional State demonstration projects requires several additional data entry requirements for the reporting of demonstration project expenditures on Part 3 of Form CB–496. The final draft version of this form was the result of comments in response to several teleconference calls with Federal and grantee staffs and a ‘webinar’’ presentation that provided detailed discussions concerning the reporting of demonstration project expenditures on Part 3. Comments were also received in response to the first Federal Register Notice (77 FR 70165 et. seq., November 23, 2012). Respondents: State (including the District of Columbia and Puerto Rico) and Tribal title IV–E agencies administering the Foster Care, Adoption Assistance and Guardianship Assistance Programs. mstockstill on DSK4VPTVN1PROD with NOTICES ANNUAL BURDEN ESTIMATES Number of respondents Instrument Form CB–496, ‘‘Title IV–E Programs Quarterly Financial Report’’ (with Part 3: ‘‘Demonstration Projects’’) ....................................................................... Form CB–496, ‘‘Title IV–E Programs Quarterly Financial Report’’ (without Part 3: ‘‘Demonstration Projects’’) ................................................................ VerDate Mar<15>2010 16:52 Jun 17, 2013 Jkt 229001 PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 Number of responses per respondent Average burden hours per response Total burden hours 30 4 23 2,760 32 4 17 2,176 E:\FR\FM\18JNN1.SGM 18JNN1

Agencies

[Federal Register Volume 78, Number 117 (Tuesday, June 18, 2013)]
[Notices]
[Pages 36550-36551]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-14435]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day-13-13XA]

Proposed Data Collections Submitted for Public Comment and
Recommendations

In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call 404-639-7570 or
send comments to Ron Otten, 1600 Clifton Road, MS-D74, Atlanta, GA
30333 or send an email to omb@cdc.gov.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology. Written comments should be received
within 60 days of this notice.

Proposed Project

Improving HIV Prevention and Treatment Outcomes Among HIV-Infected
Persons by Integrating Community Pharmacists and Clinical Sites into a
Model of Patient-Centered HIV Care--New--National Center for HIV/AIDS,
Viral Hepatitis, STD and TB Prevention (NCHHSTP), Centers for Disease
Control and Prevention (CDC).

Background and Brief Description

Medication Therapy Management (MTM) is a group of pharmacist
provided services that is independent of, but can occur in conjunction
with, provision of medication. Medication Therapy Management
encompasses a broad range of professional activities and cognitive
services within the licensed pharmacists' scope of practice and can
include monitoring prescription filling patterns and timing of refills,
checking for medication interactions, patient education, and monitoring
of patient response to drug therapy.
HIV specific MTM programs have demonstrated success in improving
HIV medication therapy adherence and persistence. While MTM programs
have be shown to be effective in increasing medication adherence for
HIV-infected persons, no MTM programs have been expanded to incorporate
primary medical providers in an effort to establish patient-centered
HIV care. To address this problem CDC has entered into a public-private
partnership with Walgreen Company (a.k.a Walgreens pharmacies, a
national retail pharmacy chain) to develop and implement a model of HIV
care that integrates community pharmacists with primary medical
providers for patient-centered HIV care. The model program will be
implemented in ten sites and will provide patient-centered HIV care for
approximately 1,000 persons.
The patient-centered HIV care model will include the core elements
of MTM as well as additional services such as individualized medication
adherence counseling, active monitoring of prescription refills and
active collaboration between pharmacists and medical clinic providers
to identify and resolve medication related treatment problems such as
treatment effectiveness, adverse events and poor adherence. The
expected outcomes of the model program are increased retention in HIV
care, adherence to HIV medication therapy and viral load suppression.
CDC requests OMB approval to collect standardized information, from
ten project sites over the three year project period. CDC also requests
approval to conduct one cycle of retrospective data collection during
the first year of the three year project period. The retrospective data
collection will provide information about clients' baseline
characteristics prior to participation in the model program which is
needed to compare outcomes before and after program implementation.
Pharmacy, laboratory and medical data will be collected through
abstraction of all participant clients' pharmacy and medical records.
Pharmacy, laboratory and medical data are needed to monitor retention
in care, adherence to therapy, viral load suppression and other health
outcomes. Program specific data, such as the number of MTM elements
completed per project site will be collected by program. Qualitative
data will be gathered from program staff through in-person or telephone
interviews.

[[Page 36551]]

The data collection will allow CDC to conduct continuous program
performance monitoring which includes identification of barriers to
program implementation, solutions to those barriers, and documentation
of client health outcomes. Performance monitoring will allow the model
program to be adjusted, as needed, in order to develop a final
implementation model that is self-sustaining and which can be used to
establish similar collaborations in a variety of clinical settings.
There is no cost to participants other than their time.

Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per Total burden
Type of respondent Form name respondents responses per response (in (in hours)
respondent hours)
----------------------------------------------------------------------------------------------------------------
Clinic Data Manager.......... Project clinic 10 1 30/60 5
characteristics
form.
Pharmacist................... Project pharmacy 10 1 30/60 5
characteristics
form.
Clinic Data Manager.......... Initial medical 10 1 50 500
abstraction form.
Clinic Data Manager.......... Follow-up medical 10 4 25 1,000
abstraction form.
Pharmacist................... Pharmacy 10 4 25 1,000
abstraction form.
Clinic and pharmacy staff.... Interview form... 60 4 45/60 180
---------------------------------------------------------------
Total.................... ................. .............. .............. .............. 2,690
----------------------------------------------------------------------------------------------------------------

Ron A. Otten,
Director, Office of Scientific Integrity, Office of the Associate
Director for Science, Office of the Director, Centers for Disease
Control and Prevention.
[FR Doc. 2013-14435 Filed 6-17-13; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.